WTC
TGTX icon

WhitTier Trust Company’s TG Therapeutics TGTX Stock Holding History

WhitTier Trust Company’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-456
Closed -$16.7K – 1315
2025
Q3 		$16.7K Buy
+456
New +$15K ﹤0.01% 936

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

WhitTier Trust Company's TGTX Position: Q4 2025 in Review

WhitTier Trust Company sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 456 shares — an estimated $16.7K sold.

WhitTier Trust Company first reported a position in TGTX in Q3 2025 and held it in 1 quarter. The position peaked at $16.7K in Q3 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • WhitTier Trust Company reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • WhitTier Trust Company sold 456 TG Therapeutics shares in Q4 2025, an estimated $16.7K.
  • WhitTier Trust Company first reported a position in TG Therapeutics in Q3 2025 and held it in 1 quarter.
  • WhitTier Trust Company's TG Therapeutics position peaked at $16.7K in Q3 2025.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on WhitTier Trust Company's 13F filing for Q4 2025, filed 26 Jan 2026.